Venclexta Tablets 50 mg & 100 mg | Uses, Safety & Information

Venclexta Tablets 50 mg and 100 mg: Product Overview

Venclexta tablets contain venetoclax, a targeted anticancer medicine used to treat certain blood cancers. Venclexta is a brand associated with venetoclax and is used under specialist medical supervision. The 50 mg and 100 mg strengths are available in applicable markets, subject to local regulatory approvals.

What Is Venclexta (Venetoclax)?

Venetoclax belongs to a class of medicines called BCL-2 inhibitors. The BCL-2 protein can help cancer cells survive. Venetoclax blocks this protein, helping trigger the death of certain cancer cells.

According to the US prescribing information, Venclexta is indicated for adults with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is also used in combination with specific medicines for certain adults with newly diagnosed acute myeloid leukaemia (AML), including patients aged 75 years or older or those unsuitable for intensive induction chemotherapy. Approved indications may differ between countries.

Potential Benefits of Venclexta Tablets

When prescribed for an appropriate indication, venetoclax may offer the following clinical benefits:

Targeted treatment: Acts on the BCL-2 protein involved in cancer-cell survival.

CLL and SLL treatment: Provides an established treatment option for eligible adults with these blood cancers.

Combination therapy for AML: Can be used with selected medicines, including azacitidine, decitabine or low-dose cytarabine, for eligible patients.

Oral administration: Tablets can be taken by mouth according to the prescribed treatment schedule.

Treatment response varies between individuals. The medicine is not suitable for every patient, and outcomes depend on the diagnosis, disease characteristics and treatment regimen.

Venclexta 50 mg and 100 mg: Dosage and Administration

The appropriate strength and dosage depend on the cancer being treated, the treatment combination, laboratory results and individual risk factors. For CLL or SLL, treatment generally starts with a gradual dose escalation to reduce the risk of tumour lysis syndrome (TLS). AML regimens follow a different schedule.

Take Venclexta exactly as prescribed by an oncologist. Do not start, stop, increase or change the dose without medical advice. Patients require appropriate laboratory monitoring, hydration and other preventive measures as directed by their healthcare team.

Possible Side Effects of Venclexta

Common or clinically significant adverse effects may include:

Low white blood cell counts, including neutropenia

Anaemia and low platelet counts

Nausea, diarrhoea or constipation

Fatigue and weakness

Respiratory infections and fever

Vomiting or swelling, depending on the treatment regimen

Important safety warning: Tumour lysis syndrome (TLS) can occur when cancer cells break down rapidly, potentially causing serious kidney problems and dangerous electrolyte changes. Serious infections and other complications are also possible. Seek urgent medical attention for symptoms such as fever, markedly reduced urination, severe weakness, confusion or an irregular heartbeat.

Tell your doctor about all medicines and supplements you take, as interactions can significantly affect venetoclax exposure. Pregnancy, breastfeeding and liver problems also require medical review.

Frequently Asked Questions (FAQs)

1. What is Venclexta 100 mg used for?

Venclexta 100 mg contains venetoclax and may be prescribed as part of an approved treatment regimen for certain blood cancers, including CLL, SLL and specific cases of AML.

2. What is the difference between Venclexta 50 mg and 100 mg?

The strengths contain different amounts of venetoclax per tablet. The prescribed strength and number of tablets depend on the treatment schedule; they are not interchangeable without medical guidance.

3. Is Venclexta chemotherapy?

Venetoclax is a targeted anticancer medicine classified as a BCL-2 inhibitor. It may be used alone or in combination with other anticancer medicines, depending on the indication.

4. Can Venclexta cause serious side effects?

Yes. TLS, severe low blood-cell counts and serious infections are important risks. Regular monitoring and following the prescribed treatment plan are essential.

5. How can international buyers enquire about Venclexta?

Healthcare professionals and pharmaceutical procurement teams may contact Cordium Pharmaceuticals Pvt Ltd to enquire about product information, market-specific regulatory requirements and potential supply arrangements. All supply is subject to applicable laws and authorisations.

Contact Cordium Pharmaceuticals Pvt Ltd

For pharmaceutical product information and international trade enquiries concerning venetoclax tablets, contact Cordium Pharmaceuticals Pvt Ltd through its official business channels. Buyers should verify product authenticity, local registration, authorised supply arrangements and import requirements before procurement.